Literature DB >> 21523678

[Chronic inflammation in patients with acute coronary syndrome and chronic kidney disease].

Aleksander Owczarek1, Magdalena Babińska, Bożena Szyguła-Jurkiewicz, Jerzy Chudek.   

Abstract

Chronic kidney disease is a worldwide growing problem in public health. It is a risk factor for complications in patients with acute coronary syndrome (ACS). Diabetes, hypertension (hypertrophy and left ventricular failure), impaired fibrinolysis and coagulation processes, as well as the rapid development of atherosclerosis (partly associated with chronic inflammation) are responsible for higher prevalence of cardiovascular diseases in patients with chronic kidney disease. Inflammatory process of unknown aetiology belongs to the so-called non-traditional risk factors in development of cardiovascular system diseases. It is thought that this process is responsible for adverse remodelling of atherosclerosis plaque and its instability which causes plaque rupture and as a result a coronary syndrome occurrence. Important inflammatory mediators, which take part in pathogenesis of ACS, are acute phase proteins such as: C-reactive protein, adhesion molecules VCAM-1, ICAM-1, selectins, plasma amyloid A, metalloproteinases, interleukins-1 and -6, tumour necrosis factor-a and vascular endothelial growth factor.

Entities:  

Mesh:

Year:  2011        PMID: 21523678

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  3 in total

Review 1.  The Prognostic Role of Red Blood Cell Distribution Width in Coronary Artery Disease: A Review of the Pathophysiology.

Authors:  Kamil Bujak; Jarosław Wasilewski; Tadeusz Osadnik; Sandra Jonczyk; Aleksandra Kołodziejska; Marek Gierlotka; Mariusz Gąsior
Journal:  Dis Markers       Date:  2015-08-26       Impact factor: 3.434

2.  Efficacy of low-fat milk and yogurt fortified with vitamin D3 on systemic inflammation in adults with abdominal obesity.

Authors:  Payam Sharifan; Mohammad Rashidmayvan; Mitra Rezaie; Majid Ghayour Mobarhan; Zahra Khorasanchi; Susan Darroudi; Azam Heidari; Fatemeh Hoseinpoor; Hassan Vatanparast; Mohamad Safarian; Saeid Eslami; Asma Afshari; Zahra Asadi; Hamideh Ghazizadeh; Mohammad Bagherniya; Hamed Khedmatgozar; Gordon Ferns
Journal:  J Health Popul Nutr       Date:  2022-03-02       Impact factor: 2.000

3.  Darbepoetin alpha reduces oxidative stress and chronic inflammation in atherosclerotic lesions of apo E deficient mice in experimental renal failure.

Authors:  Nicole Arend; Karl F Hilgers; Valentina Campean; Britta Karpe; Nada Cordasic; Bernd Klanke; Kerstin Amann
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.